

# NATIONAL HEART, LUNG, AND BLOOD ADVISORY COUNCIL

## MEETING MINUTES

October 30-31, 2003

- [I. Call to Order and Opening Remarks](#)
- [II. Review of Confidentiality & Conflict of Interest](#)
- [III. Report of the Acting Director](#)
- [IV. Barriers to Clinical Research](#)
- [V. Intramural Scientific Presentations](#)
- [VI. NHLBI T32 Training Program](#)
- [VII. Joint Initiatives with the Canadian Institutes of Health Research](#)
- [VIII. Initiatives for Fiscal Years 2004/2005](#)
- [IX. Review of Applications](#)

### **I. CALL TO ORDER AND OPENING REMARKS - Dr. Barbara Alving**

Dr. Barbara Alving, Acting Director of the National, Heart, Lung, and Blood Institute opened the meeting and welcomed the Council members to the 212th meeting of the National Heart, Lung, and Blood Advisory Council (NHLBAC).

### **Member Updates**

Dr. Robert Jesse is the new ex officio member representing the Department of Veterans Affairs. He is the Chief of Cardiology at the Richmond VA Medical Center and Professor at the Medical College of Virginia, Virginia Commonwealth University.

The Secretary has invited four distinguished individuals to serve on the Council for terms beginning November 1, 2003. While they have all accepted the secretary's invitation, they are not Official members@ until their administrative paperwork has been cleared.

The new members are: Dr. Roberto Bolli, Chief of the Division of Cardiology at the University of Louisville, Dr. Richard C. Boucher, Director of the Cystic Fibrosis/Pulmonary Research and Treatment Center at the University of North Carolina-Chapel Hill, Ms. Mary H. Deer, founding member of the American Indian Community House in New York, and Dr. Robert F. Lemanske, Professor of Medicine and Pediatrics at the University of Wisconsin.

Drs. Eliasson, Henderson, Mason, and Newberger did not attend the meeting.

## **Guests and Speakers**

Dr. Alving introduced the guests and the speakers:

### **Guests:**

Dr. Theodore Wun, Associate Professor at the University of California, Davis Cancer Center, member of the Sickle Cell Advisory Committee.

Dr. Fernando Martinez, Professor of Pediatrics at the University of Arizona, member of the Board of Extramural Advisors.

### **Speakers:**

Dr. Amy Patterson, Director of the Office of Biotechnology Activities for the Office of the Director of NIH.

Dr. Gordon Bernard, Director of the Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt University School of Medicine

Dr. Bruce McManus, Scientific Director of the Canadian Institute of Health Research.

Dr. John Barrett, Section Chief of the Allergenic Stem Cell Transplant Program in the NHLBI Intramural Program

Dr. Neal Young, Chief of the Hematology Branch in the NHLBI Intramural Program

## **New Publications**

- Pamphlets for Heart Attack Signs designed for low literacy
- Keep the Beat Heart Healthy Recipes
- Fact Sheets on Heart Truths for African Americans and Latinos
- Facts about the Dash eating plan
- Public Interest Newsletter from the NHLBI

## **II. REVIEW OF CONFIDENTIALITY & CONFLICT OF INTEREST - Dr. Barbara Alving**

The Council was reminded that according to Public Law 92-463, the Federal Advisory Committee Act, the meeting of the NHLBAC would be open to the public except during consideration of grant applications. A notice of this meeting was published in the *Federal Register* indicating that it would start at 8:30 a.m. and remain open until approximately 12:00

p.m. Dr. Alving also reminded the Council members that they are Special Government Employees and are subject to departmental conduct regulations.

### **III. REPORT OF THE ACTING DIRECTOR - Dr. Barbara Alving**

Dr. Alving reported on the status of the search for the new NHLBI Director. A search committee is in the process of being chosen and the committee will be co-chaired by Dr. Francis Collins, Director of the National Genome Institute and Dr. T.K. Li, Director of the National Institute of Alcohol Abuse and Addiction. The government is currently operating under a continuing resolution which expires October 31, 2003. The NIH is still considering the report of the Institute of Medicine and the recommendations for NIH. The NIH Roadmap is ongoing and many of the initiatives have been published in the NIH Guide for Grants and Contracts. Dr. Alving announced that Dr. John Watson, Program Director of Clinical and Molecular Medicine in the Division of Heart and Vascular Diseases, will be retiring after 27 years at the Institute.

### **IV. BARRIERS TO CLINICAL RESEARCH - Dr. Lawrence Friedman, Dr. Amy Patterson and Dr. Gordon Bernard**

Dr. Lawrence Friedman, Acting Deputy Director of NHLBI, introduced Dr. Amy Patterson, Director of the Office of Biotechnology Activities for the Office of the Director of NIH. Dr. Patterson addressed the Council on the harmonization of clinical research which is a top priority of the Roadmap Initiative. The major theme is that there are many impediments to performing clinical research. There are redundancies in the various requirements for oversight of clinical studies with respect to adverse events and conflict of interest issues between agencies and within NIH. The solution is to promote responsible conduct of high quality research and have opportunities to convene other Federal agencies to harmonize their efforts. The goal is to catalyze Federal cooperation through harmonization, standardization, and streamlining the various regulatory processes. The priority issues include harmonizing adverse event reporting requirements across agencies, clarifying the roles and responsibilities of Data Safety Monitoring Board (DSMBs), Institutional Review Board (IRBs) and other review mechanisms, reconciling requirements for auditing and monitoring of clinical trials, and devising standards for electronic submission of safety and clinical research information. Other issues include examining the application of Health Insurance Portability and Accountability Act (HIPAA) to clinical research, clarification of the interpretation of human subject regulations, examining the characteristics of central versus local IRBs, the variable approaches to providing informed consent and sharing best practices, and guidance on investment financial disclosure and conflict of interest. These issues require sustained attention and will involve outside experts as well as education and outreach to the community.

Dr. Friedman introduced Dr. Gordon Bernard, Professor at Vanderbilt University and an NHLBI Council member, who addressed Council on the status of Institutional Review Boards.

Currently Dr. Bernard is the Medical Director of the IRB at Vanderbilt University. The IRB goals are to protect human subjects as well as to adhere to regulations, communicate, and educate. The challenges which face an IRB include the increased scrutiny required by Federal regulations, expanded interpretations, increased media attention, increased legal liability, a decrease in credibility of institutions, a decrease in public trust, an increase in workload, and overlapping oversight. The growth in volume of new studies is 23% and as a result the IRB must meet for two hours each week. Consequently, members are now paid for their time and percent effort. IRBs now have new responsibilities for oversight of committees including human subject radiation and radioactive drug research committees. There are other areas including the HIPPA Privacy Board for Research and The Association for the Accreditation of Human Research Protection Programs (AAHRPP) Accreditation and Office of Human Research Protection (OHRP QI) Program. A big issue is also the complexity of review of multi-center trials which require reformatting consent/patient survey forms, input from multiple IRBs, and multiple re-reviews for each concern identified. The critical point is that all the extra effort expended does not seem to have provided any extra benefits in terms of human subject protection. The conclusion is that the processes should be streamlined to reduce effort and cost while maintaining current standards of protection.

Council commented that NIH should take a leading role in bringing this problem to the attention of the Department. HHS should establish a commission to deal with the conflicting and repetitive requirements between agencies and resolve conflicts between OHRP and NIH. The regulatory burdon has become so heavy that clinical research as well as public health-oriented research has been compromised. Council passed a resolution to present to Dr. Zerhouni which states:

“The National Heart, Lung, and Blood Advisory Council expresses concern that the complexity of the regulation of the participation of human subjects in research settings is limiting scientific progress without necessarily enhancing the protection of subjects from research risks. Because research of this type is regulated by the NIH, FDA, and OHRP and others, the NHLBI Advisory Council asks the Office of the Director of the NIH to petition Secretary Thompson to appoint a single commission with the charge to harmonize regulations among entities while providing the best possible protection for human subjects in research trials.”

## **V. INTRAMURAL SCIENTIFIC PRESENTATIONS: BONE MARROW TRANSPLANTATION PROGRAM**

Dr. Elizabeth Nabel, Director of the Clinical Intramural Program at NHLBI, introduced two scientists from the Hematology Branch of the NHLBI Division of Intramural Research. The NHLBI hematology program has had a longstanding interest in stem cell biology including graft engineering in the leukemias and stem cell failure.

Dr. John Barrett , Chief of the Allogeneic Stem Cell Transplantation Section, described the progress which has been made in allogeneic stem cell transplantation utilized in treating leukemias and lymphomas which are not responsive to regular treatment. Dr. Barrett described a sequence of protocols which have been modified over the last 10 years to provide subjects with better outcomes. The results have shown that the graft versus leukemia response is a major contributor to success rate. The limitations include toxicity, graft-versus host disease, viral reactivation, and relapse. In 1993 a study was conducted using HLA-matched siblings between the ages of 10 and 55 where various options were attempted including increasing the dose of CD 34 cells, using Granulocyte Colony Stimulating Factor (GCSF) to increase T cells, selective enrichment of CD 34 cells, and the use of acyclovir to reduce the incidence of cytomegalovirus infection. As a result disease free survival rose from 37 % to 46%. The next decade of research will utilize selective depletion of T cells to reduce the need for immunosuppression and leukemia-specific T cell therapy. Dr. Neil Young, Chief of the Hematology Branch, described studies on the pathophysiology of aplastic anemia (AA) where a reduction in stem cells is evident. Studies have shown that immunosuppression improves the outcome for these patients. These patients have conditions which promote T cell attack of cellular targets. For example, AA patients have Paroxysmal Nocturnal Hemoglobinuria (PNH) where there is a gene defect in the synthesis of a membrane anchor protein. An aggressive T cell attack is mounted as a result of the gene defect and the immune response causes severe damage. Dr. Young noted that the NIH Clinical Center is the largest referral center for aplastic anemia.

## **VI. NHLBI T32 TRAINING PROGRAM - Dr. Lawrence Friedman**

Dr. Friedman presented the recommendation for a T32 funding policy. The subcommittee of Council which studied T32 funding did not recommend a budget cap for T32s. The concern remained, however, that tightening the budget in future years will make it difficult for Type 1 T32s to obtain funding. After analysis of prior year data, it was recommended to have a set-aside of at least 15% of the awards for Type 1 grants. Also it was recommended that another application receipt date be added to deal effectively with the growing volume of T32 applications. The receipt dates would be January 10 and May 10. Applications would be funded twice a year after the October and February councils. The Council agreed with these recommendations and emphasized the importance of these training programs. Dr. Friedman presented the recommendation for a T32 funding policy. The subcommittee of Council which studied T32 funding did not recommend a budget cap for T32s. The concern remained, however, that tightening the budget in future years will make it difficult for Type 1 T32s to obtain funding. After analysis of prior year data, it was recommended to have a set-aside of at least 15% of the awards for Type 1 grants. Also it was recommended that another application receipt date be added to deal effectively with the growing volume of T32 applications. The receipt dates would be January 10 and May 10. Applications would be funded twice a year after the

October and February councils. The Council agreed with these recommendations and emphasized the importance of these training programs.

## **VII. JOINT INITIATIVES WITH THE CANADIAN INSTITUTES OF HEALTH RESEARCH- Dr. Bruce McManus**

Dr. McManus is the Scientific Director of the Institute of Circulatory and Respiratory Health (ICRH) of the Canadian Institutes of Health Research (CIHR). The mission of the CIHR is to do biomedical and clinical research, and to promote the health of the Canadian people. There are thirteen Institutes and the number of grants funded has increased significantly. ICRH and NHLBI are jointly sponsoring three initiatives including the Clinical Consortium to Improve Resuscitation Outcomes, Cellular and Molecular Imaging of Cardiovascular, Pulmonary and Hematopoietic Systems, and Inflammation and Thrombosis. These initiatives are currently posted in the NIH Guide for Grants and Contracts and will be funded in FY 2004. It is hoped that joint sponsorship will foster more interactions between Canada and the United States in basic and clinical research.

## **VIII. INITIATIVES FOR FISCAL YEARS 2004/2005 - Dr. Lawrence Friedman, Dr. James Kiley, Council Members**

Seventeen initiatives as well as three Specialized Centers of Clinically Oriented Research were presented to Council. Each initiative is summarized below. Council comments are also noted.

### **1. TITLE: Asthma Exacerbations: Mechanisms of Resolution**

**OBJECTIVES:** The objective is to promote clinical and basic research that will elucidate the biologic mechanisms of resolution following asthma exacerbations.

In response to questions from Council, staff emphasized that the study would focus on the resolution not the trigger of acute asthma exacerbation. Council was enthusiastic for this initiative.

### **2. TITLE: Community-Responsive Interventions to Reduce Cardiovascular Risk in American Indians and Alaska Natives**

**OBJECTIVES:** The purpose of this initiative is to test the effectiveness of interventions for improvement in behavioral cardiovascular disease (CVD) risk factors such as obesity, diet, smoking, sleep restriction, stress, and sedentary lifestyle in American Indian/Alaska Native (AI/AN) populations. These lifestyle-related risk factors are important targets for primary prevention of CVD. The initiative concept was developed in consultation with AI/AN Tribes, recognizing the government-to-government relationship between AI/AN Tribes and the United

States, and incorporates recommendations of a working group of AI/AN health experts. The long-term goal is to reduce health disparities in AI/AN. This initiative focuses on primary prevention, an important approach that can contribute to that goal.

Council considered this to be an important initiative and that the timing was good. They indicated that the emphasis should be on the interventions and to be aware of the limitations.

**3. TITLE:** Enhancing the Use of Longitudinal Data on Cardiovascular Disease and its Risk Factors in Older Adults: The Cardiovascular Health Study (CHS)

This proposal is different from the usual BEA initiative in that it requests approval of a concept rather than a specific research activity. Large longitudinal studies provide unique resources, allowing many questions to be addressed that are outside the scope of the original primary study aims. Cohorts for longitudinal studies are difficult to establish and expensive to maintain. During the study, it is important to take advantage of opportunities for ancillary studies as long as they do not compromise the primary investigations of the project. The end of the primary study often provides additional opportunities to get new information from the cohort, either by analysis of existing data or samples or by collecting additional information from cohort members.

At present, when the objectives of the primary study are met, only two options are available: 1) funding stops and, in most cases, the study infrastructure and access to the cohort collapses or 2) new research goals are added and the study is funded by NHLBI for another cycle. This proposal provides a third alternative, an option to preserve key study resources and potential access to the cohort using a mechanism to transfer responsibility for subsequent study design, management and support to interested investigators willing to seek funding for their individual research proposals. This proposal stresses the need to encourage participation by new investigators and will expand access to the original study data, sample repositories and the cohort for the general research community. The Cardiovascular Health Study (CHS), a study currently scheduled to end in 2005, will be used to illustrate a concrete example of this approach.

Council commented that there was tremendous value in the CHS study and the data sets generated and that this proposal would set a significant precedent. The study has considerable momentum and it should be continued.

# NATIONAL HEART, LUNG, AND BLOOD ADVISORY COUNCIL

## MEMBER ROSTER

### CHAIRPERSON

ALVING, Barbara M., M.D. (2004)  
Acting Director  
National Heart, Lung, and Blood Institute  
National Institutes of Health  
Bethesda, MD 20892  
(Also an Ex Officio member)

### MEMBERS

AUSTIN, Melissa A., Ph.D. (2004)  
Professor  
Department of Epidemiology  
School of Public Health and Community Medicine  
University of Washington  
Seattle, WA 98195

BERNARD, Gordon R., M.D. (2006)  
Director  
Division of Allergy, Pulmonary and Critical  
Care Medicine  
Vanderbilt University School of Medicine  
Nashville, TN 37232

BOLLI, Roberto, M.D. (2007)  
Chief  
Division of Cardiology  
University of Louisville  
Louisville, Kentucky 40202

BOUCHER, Richard C., Jr., M.D. (2007)  
Director  
Cystic-Fibrosis/Pulmonary Research and  
Treatment  
University of North Carolina, Chapel Hill  
Chapel Hill, North Carolina 27599

BYRNES, Carolyne Sue (2004)  
Executive Director  
LAM Foundation  
Cincinnati, OH 45241

COSTANZO, Maria R., M.D. (2006)  
Medical Director  
Midwest Heart Specialists  
Edward Cardiovascular Institute  
Naperville, IL 60540

DEER, Mary H., R.N. (2007)  
Program Coordinator  
National Indian Women's Health Resource Ctr.  
Tahlequah, Oklahoma 74464

DRAZEN, Jeffrey M., M.D. (2004)  
Editor-In-Chief  
New England Journal of Medicine  
Boston, MA 02115

EAGLE, Kim A., M.D. (2006)  
Albion Walter Hewlett Professor of  
Internal Medicine  
Cardiovascular Center  
University of Michigan  
Ann Arbor, MI 48109

HENDERSON, Frances C., Ed.D. (2006)  
Professor and Dean  
School of Nursing  
Alcorn State University  
Natchez, MS 39120

LEMANSKE, Robert F., Jr., M.D. (2007)  
Professor of Pediatrics and Medicine  
University of Wisconsin Hospital  
Madison, Wisconsin 53792

MASON, Robert J., M.D. (2005)  
Professor  
Department of Medicine  
National Jewish Medical Research Center  
University of Colorado  
Denver, CO 80206

NEWBURGER, Jane W., M.D. (2005)  
Associate Cardiologist-in-Chief

Department of Cardiology  
Children's Hospital  
Boston, MA 02115

NGUYEN, Ngai X., M.D. (2006)  
Private Practitioner  
San Jose, CA 95113

PRASAD, Ananda S., M.D., Ph.D. (2004)  
Professor  
Department of Internal Medicine  
University Health Center  
Wayne State University  
Detroit, MI 48201

THOMAS, George, M.D. (2005)  
President and CEO  
Bradenton Cardiology Center  
Bradenton, FL 34205

TOY, Pearl T., M.D. (2004)  
Professor  
Department of Laboratory Medicine  
School of Medicine  
University of California, San Francisco  
San Francisco, CA 94143

VAN HORN, Linda V., Ph.D. (2005)  
Professor  
Department of Preventive Medicine  
Northwestern University Medical School  
Chicago, IL 60611

#### **EX OFFICIO MEMBERS**

ELIASSON, Arn H., M.D.  
Chief  
Pulmonary & Critical Care Medicine Service  
Walter Reed Army Medical Center  
Washington, DC 20307

JESSE, Robert C., M.D.  
Cardiology Section  
McGuire Veterans Affairs Medical Center  
Richmond, VA 23249

THOMPSON, Tommy G.  
Secretary  
Department of Health and Human Services  
Washington, DC 20201

ZERHOUNI, Elias A., Jr., M.D.  
Director  
National Institutes of Health  
Bethesda, MD 20892

#### **EXECUTIVE SECRETARY**

BEEBE, Deborah, Ph.D.  
Director  
Division of Extramural Affairs  
National Heart, Lung, and Blood Institute  
National Institutes of Health  
Bethesda, MD 20892

Updated 3/25/04

